13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
Showing 1 to 6 of 6 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCT2021200035 | 22/02/2021 | 24/12/2020 | Relapsing Forms of multiple sclerosis (RMS) study of Bruton's Tyrosine Kinase (BTK) inhibitor Tolebrutinib (SAR442168) Relapsing Forms of multiple sclerosis (RMS) study of Bruton's Tyrosine Kinase (BTK) inhibitor Tolebr ... | A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio) in participants with relapsing forms of multiple sclerosis - GEMINI 1 A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide ( ... | Relapsing Multiple Sclerosis | Drug: SAR442168 (Tolebrutinib) Pharmaceutical form: Tablet, Route of administration: Oral Drug: Placebo to match SAR442168 (Tolebrutinib) Pharmaceutical form: Tablet, Route of administration: Oral Drug: Teriflunomide HMR1726 Pharmaceutical form: Tablet, Route of administration: Oral Drug: Placebo to match Teriflunomide Pharmaceutical form: Tablet, Route of administration: Oral Drug: SAR442168 (Tolebrutinib) Pharmaceutical form: Tablet, Route of administration: Oral Drug: Placeb ... | Tanaka Tomoyuki | NULL | Recruiting | >= 18age old | <= 55age old | Both | 900 | Phase 3 | Bulgaria;Canada;Czechia;Estonia;Spain;United States;Belarus;China;Finland;Germany;Italy;Lithuania;Poland;Romania;Russian Federation;Sweden;Taiwan;Turkey;Ukraine;Denmark;Japan Bulgaria;Canada;Czechia;Estonia;Spain;United States;Belarus;China;Finland;Germany;Italy;Lithuania;Po ... |
2 | NCT04410978 (ClinicalTrials.gov) | June 30, 2020 | 28/5/2020 | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebr ... | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide ( ... | Relapsing Multiple Sclerosis | Drug: Tolebrutinib;Drug: Teriflunomide HMR1726;Drug: Placebo to match Tolebrutinib;Drug: Placebo to match Teriflunomide Drug: Tolebrutinib;Drug: TeriflunomideHMR1726;Drug: Placebo to match Tolebrutinib;Drug: Placebo to m ... | Sanofi | NULL | Recruiting | 18 Years | 55 Years | All | 900 | Phase 3 | United States;Austria;Belarus;Bulgaria;Canada;China;Czechia;Denmark;Estonia;Finland;Germany;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine United States;Austria;Belarus;Bulgaria;Canada;China;Czechia;Denmark;Estonia;Finland;Germany;Italy;Ja ... |
3 | NCT04410991 (ClinicalTrials.gov) | June 11, 2020 | 28/5/2020 | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebr ... | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide ( ... | Relapsing Multiple Sclerosis | Drug: Tolebrutinib;Drug: Teriflunomide HMR1726;Drug: Placebo to match Tolebrutinib;Drug: Placebo to match Teriflunomide Drug: Tolebrutinib;Drug: TeriflunomideHMR1726;Drug: Placebo to match Tolebrutinib;Drug: Placebo to m ... | Sanofi | NULL | Recruiting | 18 Years | 55 Years | All | 900 | Phase 3 | United States;Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom United States;Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czechia;France;Germany;Greece;Hungary;In ... |
4 | NCT03856619 (ClinicalTrials.gov) | March 27, 2019 | 25/2/2019 | To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sc ... | A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patient ... | Relapsing Multiple Sclerosis | Drug: TERIFLUNOMIDE HMR1726 | Sanofi | NULL | Active, not recruiting | 18 Years | N/A | All | 117 | Phase 4 | India |
5 | NCT02046629 (ClinicalTrials.gov) | May 2014 | 23/1/2014 | A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chi ... | An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tab ... | Multiple Sclerosis | Drug: Teriflunomide HMR1726;Drug: cholestyramine | Sanofi | NULL | Completed | 18 Years | 45 Years | Both | 12 | Phase 1 | China |
6 | NCT01863888 (ClinicalTrials.gov) | October 2013 | 23/5/2013 | Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis | Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in th ... | Multiple Sclerosis | Drug: teriflunomide HMR1726;Drug: cholestyramine;Drug: charcoal | Sanofi | NULL | Completed | 18 Years | 55 Years | Both | 70 | Phase 3 | Belgium;Germany;Netherlands |